Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner: PRESSURE BIOSCIENCES, INC.				
Application No./Patent No.: 09/901,297 Filed/Issue Date: 07-09-2001				
Entitled: PRESSURE-CONTROLLED NUCLEIC ACID HYBRIDIZATION				
PRESSURE BIOSCIENCES, INC. (Name of Assignee) A CORPORATION (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)				
	однос, од., согросия, ранистанр, интогоку, дочонинени аденсу, сто.,			
states that it is:				
1. the assignee of the entire right, title, and interest; or				
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)				
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/s the United States Patent and Trademark Office at Reel copy therefore is attached. OR	patent identified above. The assignment was recorded in, Frame, or for which a			
B. A chain of title from the inventor(s), of the patent application/p	patent identified above, to the current assignee as follows:			
1. From: INVENTORS	-			
The document was recorded in the United States P				
	or for which a copy thereof is attached.			
2. From: BIOSEQ, INC.				
The document was recorded in the United States P	atent and Trademark Office at			
Reel <u>010569</u> , Frame <u>0986</u>	, or for which a copy thereof is attached.			
3. From: BBI BIOSEQ, INC.	To: PBI BIOSEQ, INC.			
The document was recorded in the United States P	atent and Trademark Office at			
Reel, Frame	or for which a copy thereof is attached.			
Additional documents in the chain of title are listed on a supp	plemental sheet.			
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.				
[NOTE: A separate copy (i.e., a true copy of the original assignme accordance with 37 CFR Part 3, to record the assignment in the re	ent document(s)) must be submitted to Assignment Division in ecords of the USPTO. See MPEP 302.08]			
The undersigned (whose title is supplied below) is authorized to act on be	ehalf of the assignee.			
/Catherine M. McCarty/	December 12, 2008			
Signature	Date			
Catherine M. McCarty	617-395-7000			
Printed or Typed Name	Telephone Number			
Patent Attorney				
Title				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

STATEMENT UNDER 3.73(b) SUPPLEMENTAL SHEET

Applicant/Patent Owner: PRESSURE BIOSCIENCES, INC.

Application Number: 09/901,297 File Date:07-09-2001

Entitled: PRESSURE-MODULATED ION ACTIVITY

CHAIN OF OWNERSHIP CONTINUED

4. From: PBI BIOSEQ, INC. To: PRESSURE BIOSCIENCES, INC.

A copy of the assignment is attached. As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

Respectfully submitted,

By: <u>/Catherine M. McCarty/</u>
Catherine M. McCarty (Reg. No. 54,301)

LOWRIE, LANDO & ANASTASI, LLP

Riverfront Office Park One Main Street

Cambridge, MA 02142

Tel: (617) 395-7087 Fax:: (617-395-7070

Date: December 12, 2008

The Commonwealth of Massachusetts William Francis Galvin

Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512

DATE BEFORE	Articles of Amendment FORM AUST	BE TYPED
(General Lav	ws, Chapter 156D; Section 10.06; 950 CMR 113.33)	
Exact name of corporation: BBI BioSeq	, Inc.	
Registered office address: 375 West Stree	et, West Bridgewater, MA 02379	
	(number, street, city or town, state, zip code)	
These articles of amendment affect article((s): One	
	(specify the number(s) of article(s) being amended (I-VI))	
Adopted and approved on:		by
	(month, day, year)	•
Check the appropriate box below:		
the incorporators.		
the board of directors without sh	areholder approval and shareholder approval was not required.	
the board of directors and the sha	areholders in the manner required by law and the articles of organization.	

State the article number and the text of the amendment. If the amendment authorizes an exchange, or effects a reclassification or cancellation, of issued shares, state the provisions for implementing the action unless contained in the text of the amendment.

MA005 - 08/12/2004 C T System Online

12/12/44

15601006 0/02/04

WIL	HOUT PAR VALUE	ţ	WITH PAR VALUE	
ТҮРЕ	NUMBER OF SHARES	TYPE	NUMBER OF SHARES	PAR VALU

The foregoing amendment(s) will become effective when these Articles of Amendment are filed in accordance with General Laws, Chapter 156D, § 1.25 unless these articles specify, in accordance with the vote adopting the amendment a later effective date not

more than ninety days after such filing, in which event the amendment will become effective on such later date.

The Commonwealth of Massachusetts William Francis Galvin

Secretary of the Commonwealth One Ashburton Place, Boston, Massachusetts 02108-1512

Attachment Sheet

Articles of Amendment

BBI BioSeq, Inc.

ARTICLE I: The name by which the corporation shall be known: PBI BioSeq, Inc.

Signed by heart behind, Duester & Saubolibe	
(Please check appropriate box) Chairman of the Board	
President Other Officer Court-appointed fiduciary	
on this day of January	2005

MA006 - 08/12/2004 C T System Online

COMMONWEALTH OF MASSACHUSETTS

William Francis Galvin

Secretary of the Commonwealth
One Ashburton Place, Boston, Massachusetts 02108-1512

21147

Articles of Amendment (General Laws, Chapter 156D, Section 10.06)

I hereby certify that upon examination of these Articles of Amendment, it appears that the provisions of the General Laws relative thereto have been

complied with, ar	nd the filing fee in the amount of \$_\text{OQ} having been
	are deemed to have been filed with me this
1	day of Feb 20 05 at 1:40 a.m./p.n
time	·
Effective date:	
	4
Ş	Splan Francis Ballin
	WILLIAM FRANCIS GALVIN
	Secretary of the Commonwealth
	num filing fee \$100.00 per article amended, stock increase 0 shares plus \$100 for each additional 100,000 shares or ar
то	BE FILLED IN BY CORPORATION
	Contact Information:
Ann C. I	Meltzer, c/o Brown Rudnick Berlack Israels LLP
	One Financial Center
	Boston, Massachusetts 02111
T-1	(617) 856-8200
Telephone:	
Email:	

A copy of this filing will be available on-line at www.sec.state.ma.us/cor once

the document is filed.

513779

Examine

Name a

c

Docket No.: P2028-9000 Assignment- Page 1 of 4

ASSIGNMENT

For valuable consideration, PBI BIOSEQ, INC., a corporation of Massachusetts having a place of business at 14 Norfolk Avenue, South Easton, MA 02375; and its successors and assigns (collectively hereinafter called "the Assignor); hereby assigns to PRESSURE BIOSCIENCES, INC., a corporation of Massachusetts having a place of business at 14 Norfolk Avenue, South Easton, MA 02375 (collectively hereinafter called "the Assignee"), the entire right, title and interest throughout the world in the inventions and improvements which are subject of patents and patent applications listed on Schedule A and including said patents, applications, and any and all continuations, continuations-in-part, and divisional applications, and any and all United States and foreign patents (including reissues, reexaminations, extensions), utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing dates of said applications under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and Assignor hereby declares its acceptance of said assignment.

Docket No.: P2028-9000 Assignment- Page 3 of 4

	PRESSURE BIOSCIENCES, INC.		
	(signature)		
	Name: RUHAM TO SUMMACHER		
	Title:CEO		
Witnessed by:			
Name: Joseph Danais	Date: 10/23/08		

Docket No.: P2028-9000 Assignment- Page 2 of 4

In witness whereof, Assignor has caused this Assignment to be signed in its corporate name by its duly authorized officers.

PBI BIOSEQ, INC..

DATE: Other 23, 2008

Name: Littles T. Superior

Title: Position

STATE OF Structure

On 10/20/08, before me, the undersigned, a notary public for the State of Man there personally appeared the house of the person whose name is subscribed to this Assignment, who acknowledged having executed the same in his authorized

capacity and that by his signature on this Assignment, the person or the entity upon behalf of which

WITNESS my hand and official seal.

he acted, executed this Assignment.

Docket No.: P2028-9000 Assignment- Page 4 of 4

SCHEDULE A

	Application		Patent	
Client-Matter #:	#:	Filing Date:	#:	Issue Date:
P2028-7000 10	10/134054	26-Apr-2002		
P2028-7003 30	08/793213	28-Oct-1997	6036923	14-Mar-2000
P2028-7005 US	09/214250	01-Jul-1997	6635469	21-Oct-2003
P2028-7007 19	08/903615	30-Jul-1997	6245506	12-Jun-2001
P2028-7011 19	08/962280	31-Oct-1997	6111096	29-Aug-2000
P2028-7015 30	09/010892	22-Jan-1998	6127534	03-Oct-2000
P2028-7017 30	09/016062	30-Jan-1998	6274726	14-Aug-2001
P2028-7018 10	09/035652	05-Mar-1998	6258534	10-Jul-2001
P2028-7020 31	09/083651	22-May-1998	6120985	19-Sep-2000
P2028-7025 30	09/165829	02-Oct-1998	6270723	07-Aug-2001
P2028-7029 20	10/770241	02-Feb-2004		
P2028-7029 30	09/924266	07-Aug-2001	6696019	24-Feb-2004